ICARE Social Media Post June 2023

FDA Advisory Committee Recommendation: Olaparib for Prostate Cancer Treatment

Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a BRCA mutation would benefit.

⁠Use these link to learn more:



Permanent link to this article: https://inheritedcancer.net/post61623/